PFE - Pfizer Inc.

NYSE - NYSE Delayed Price. Currency in USD
38.65
+0.29 (+0.76%)
At close: 04:03PM EDT
38.74 +0.09 (+0.23%)
Pre-Market: 07:00AM EDT
Stock chart is not supported by your current browser
Previous Close38.36
Open38.48
Bid38.61 x 3000
Ask38.79 x 800
Day's Range38.47 - 39.01
52 Week Range36.17 - 54.93
Volume18,240,463
Avg. Volume24,711,440
Market Cap218.191B
Beta (5Y Monthly)0.59
PE Ratio (TTM)7.62
EPS (TTM)5.07
Earnings DateJul 26, 2023 - Jul 31, 2023
Forward Dividend & Yield1.64 (4.24%)
Ex-Dividend DateMay 11, 2023
1y Target Est46.80
  • Motley Fool

    Could Pfizer Have an Ozempic Killer on the Way?

    It wasn't because so many patients were newly diagnosed with type 2 diabetes. Instead, Ozempic gained widespread popularity for helping people lose weight. A sibling product, Wegovy, a higher-dose version of the active ingredient in Ozempic that is actually approved for weight loss, has flown off pharmacies' shelves as well.

  • Motley Fool

    Looking for Passive Income at a Decent Price? Buy These 2 Stocks

    Many investors would love to buy passive income stocks with a high dividend yield, a sustainable level of earnings coverage of the dividend, and a cheap valuation. For instance, Zoloft, Xanax, Lyrica, Viagra, and Lipitor are just a few of the older household-name drug brands that Viatris (NASDAQ: VTRS) counts in its portfolio of generic medicines, and while none are new medicines, they're each indispensable to this day. Viatris' forward dividend yield is presently above 5.2%, which is on the high side compared to the market's average yield of around 1.6%.

  • Motley Fool

    3 Dividend Stocks You Can Buy Without Any Hesitation

    Three Motley Fool contributors identified dividend stocks that should be easy buy decisions for investors. Here's why they think Bristol Myers Squibb (NYSE: BMY), Gilead Sciences (NASDAQ: GILD), and Pfizer (NYSE: PFE) are investments you can make in June without any hesitation. David Jagielski (Bristol Myers Squibb):  Bristol Myers Squibb has been paying dividends for more than 90 consecutive years.

  • Motley Fool

    Why Shares of BioNTech Rose Friday

    Shares of BioNTech (NASDAQ: BNTX) were up as by much as 5.3% on Friday before closing the session up 3.85% after the biotech company announced positive news regarding a clinical trial for its non-small cell lung cancer therapy candidate. The company focuses on immunotherapies to treat cancer, infectious diseases, and other diseases. BioNTech's shares have been sliding because sales of Comirnaty, the COVID-19 vaccine it developed with Pfizer, are falling.

  • Zacks

    Pharma Stock Roundup: FDA Okays PFE RSV Jab for Elderly, AZN Ends Brazikumab Studies

    FDA approves Pfizer's (PFE) RSV vaccine for older adults and AstraZeneca (AZN) and Merck's (MRK) Lynparza for BRCA-mutated metastatic castration-resistant prostate cancer

  • Motley Fool

    Why Biohaven Stock Caught Fire This Week

    Shares of the clinical-stage biopharma Biohaven (NYSE: BHVN) rocketed higher by 33.5% over the first four days of trading this week, according to data provided by S&P Global Market Intelligence. The big gain was sparked by the company's research and development day presentation held on Wednesday. Highlights from Biohaven's presentation include the unexpected Food and Drug Administration (FDA) regulatory filing for the experimental spinocerebellar ataxia type 3 drug troriluzole, status updates on its closely watched epilepsy program, and a clinical strategy overview for its newly acquired neuroinflammatory asset BHV-8000.

  • Zacks

    Pfizer (PFE) Down 1.1% Since Last Earnings Report: Can It Rebound?

    Pfizer (PFE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Zacks

    Biohaven (BHVN) Stock up 8% on Encouraging Pipeline Updates

    At its R&D Day, Biohaven (BHVN) provides updates on its pipeline. It also announced submission of a regulatory filing seeking approval for troriluzole in SCA3, an ultra-rare disorder.

  • Reuters

    UPDATE 2-Pfizer says its experimental antibiotic combo can treat some superbug infections

    Pfizer Inc said on Thursday data from late-stage trials showed its experimental combination of antibiotics was effective in treating deadly infections caused by drug-resistant bacteria. Deaths from antibiotic-resistant bacteria, also known as superbugs, have been on the rise globally, and health regulators have called for the development of newer treatments as resistance to older antibiotics grows. The late-stage studies compared the experimental combination of the antibiotics aztreonam-avibactam (ATM-AVI) and existing generic drug metronidazole with a combination of two older antibiotics - meropenem and colistin - to treat complicated intra-abdominal infections and types of hospital-acquired pneumonia.

  • Business Wire

    Phase 3 Studies of Pfizer’s Novel Antibiotic Combination Offer New Treatment Hope for Patients with Multidrug-Resistant Infections and Limited Treatment Options

    NEW YORK, June 01, 2023--Pfizer Inc. (NYSE: PFE) today announced positive results from the Phase 3 program comprising the REVISIT (NCT03329092) and ASSEMBLE (NCT03580044) studies evaluating the efficacy, safety, and tolerability of the novel investigational antibiotic combination aztreonam-avibactam (ATM-AVI) in treating serious bacterial infections due to Gram-negative bacteria, including metallo-β-lactamase (MBL)-producing multidrug-resistant pathogens for which there are limited or no treatme

  • Motley Fool

    Have $2,000? 2 Remarkable Growth Stocks to Buy Right Now

    Regardless of your investing experience or risk tolerance, putting cash into stocks takes a certain tolerance for volatility and uncertainty. Investing in wonderful businesses, diversifying the ones you own, holding onto those great companies through the market's highs and lows, and avoiding traps like market timing can help you outpace the returns of the average retail investor through the years. Pfizer (NYSE: PFE) caught the attention of many investors when it became one of the leading contenders in the race to get a COVID-19 vaccine to market.

  • Zacks

    Pfizer's (PFE) RSV Vaccine for Older Adults Gets FDA Approval

    The FDA approves Pfizer's (PFE) RSV vaccine, Abrysvo, for older adults, making it the second RSV vaccine to be approved by the regulatory agency.

  • Reuters

    UPDATE 2-US FDA approves Pfizer's RSV vaccine

    The U.S. Food and Drug Administration on Wednesday approved Pfizer Inc's respiratory syncytial virus (RSV) vaccine for older adults, making it the second shot against the common respiratory disease that can be fatal for seniors. The approval comes less than a month after the FDA approved a similar shot by rival GSK Plc. Pfizer's vaccine was approved for people aged 60 and older, the company said, the same age group as GSK's shot. In a late-stage study, Pfizer's vaccine, to be sold under the brand name Abrysvo, was 67% effective among those aged 60 and older with two or more symptoms of RSV, and 85.7% against severe illness defined by three or more symptoms.

  • Business Wire

    U.S. FDA Approves ABRYSVO™, Pfizer’s Vaccine for the Prevention of Respiratory Syncytial Virus (RSV) in Older Adults

    NEW YORK, May 31, 2023--Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved ABRYSVO™ (Respiratory Syncytial Virus Vaccine), the company’s bivalent RSV prefusion F (RSVpreF) vaccine, for the prevention of lower respiratory tract disease caused by RSV in individuals 60 years and older. ABRYSVO is unadjuvanted and composed of two preF proteins selected to optimize protection against RSV A and B strains and was observed to be safe and effective.

  • Motley Fool

    Why Pfizer Stock Is Perking Up Today

    Shares of pharma titan Pfizer (NYSE: PFE) were up by 2.24% on moderate volume as of 2:29 p.m. ET Wednesday afternoon. Earlier Wednesday, The Wall Street Journal published a column questioning whether investors have turned too bearish on COVID-19 vaccine-makers like Pfizer. Pfizer's shares have fallen by as much as 30% this year in response to the anticipated drop in sales for its COVID-19 vaccine Comirnaty and antiviral treatment Paxlovid.

  • Zacks

    Pfizer (PFE) Posts Upbeat Data From Hemophilia Drug Study

    Data from a late-stage study shows that treatment with Pfizer's (PFE) experimental anti-TFPI inhibitor led to a significant reduction in annualized bleeding rate in hemophilia A and B patients.

  • Motley Fool

    Does Pfizer Have a Weight-Loss Pill That's Better Than Ozempic?

    A highly lucrative weight-loss market could be the growth opportunity Pfizer needs to make the stock a better buy.

  • Motley Fool

    2 Ultra-Safe Dividend Stocks to Load Up On Right Now

    Which top-shelf dividend stocks are worth buying right now? Allstate (NYSE: ALL) and Pfizer (NYSE: PFE) are two near-locks to produce healthy levels of capital appreciation over the next five to 10 years. Allstate's 2023 Q1 earnings report isn't exactly a confidence-inspiring read.

  • Zacks

    Valneva (VALN) Stock Down 53% in the Past Year: Here's Why

    The European Commission's revised advance purchase agreement jeopardizes Valneva's (VALN) COVID-19 vaccine program.

  • Zacks

    Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know

    Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

  • Reuters

    Pfizer's hemophilia therapy reduces bleeding in late-stage study

    U.S. drugmaker Pfizer Inc said on Tuesday late-stage study data for its experimental hemophilia therapy showed superiority to the current standard of care treatment in reducing bleeding rates in patients. The therapy, marstacimab, met its main trial goal, demonstrating superiority to factor replacement therapies, with a 92% reduction in bleeding in patients with severe hemophilia A and moderately severe to severe hemophilia B, Pfizer said. Hemophilia hampers the body's ability to make blood-clotting proteins, leading to prolonged bleeding following injuries or surgery, and it primarily affects males, according to government data.

  • Business Wire

    Pfizer Announces Positive Marstacimab Results from Pivotal Phase 3 Hemophilia A and B Trial

    NEW YORK, May 30, 2023--Pfizer Inc. (NYSE: PFE) today announced that the pivotal Phase 3 BASIS clinical trial (NCT03938792) evaluating marstacimab has met its primary endpoints, having demonstrated statically significant and clinically meaningful effects. Marstacimab, a novel, investigational anti-tissue factor pathway inhibitor (anti-TFPI) being studied for the treatment of hemophilia A or B for people without inhibitors to Factor VIII (FVIII) or Factor IX (FIX), was administered weekly with fl

  • Motley Fool

    Pfizer's Heading for a Patent Cliff. Is the Stock Still a Buy?

    The company also continues to benefit from sales of blockbusters including blood thinner Eliquis and oncology drug Ibrance. In fact, Pfizer expects patent losses alone to lead to $17 billion in lost revenue from 2025 through 2030. In spite of these upcoming obstacles, is Pfizer still a buy?

  • Zacks

    EMA Panel Endorses Novavax's (NVAX) COVID Jab for Full Approval

    Novavax's (NVAX) protein-based COVID-19 vaccine gets recommendation for full marketing authorization in COVID-19 patients from European Medicines Agency.